Bristol-Myers Squibb Co. et al v. Merck & Co Inc., No. 1:2014cv01131 - Document 213 (D. Del. 2016) case opinion from the District of Delaware US Federal District Court.
Parties, docket activity and news coverage of federal case Gilead Sciences, Inc. v . Merck & Co, Inc. et al, case number 5:13-cv-04057, from California Northern Court.
Parties, docket activity and news coverage of federal case UNITED STATES OF AMERICA et al. v. MERCK & CO., case number 2:10-cv-04374, from Pennsylvania Eastern Court.
The Supreme Court has dismissed Apotex's leave to appeal from Apotex Inc. v. Merck & Co., Inc., 2015 FCA 171. The Supreme Court has provided the following summary of the case: The respondents (collectively, "Merck") own the product-by- process 380 patent for the anti-cholesterol drug lovastatin (“AFI-1 process”), ...
L. Pavlu˚1, J. Vosáhlová1, H. Klierová2, M. Prouza2, K. Demnerová2 and V. Brenner1 ... soils while PCB-co-metabolizing strains were routinely iso- lated from contaminated soil by the enrichment on biphenyl. (Hickey et al. 1993). Hernandez et al. ... Correspondence to: V. Brenner, Institute of Microbiology, Academy of.
This bacterium, which was shown to belong to the α-Proteobacteria, was named Afipia felis (Brenner et al., 1991). Brenner et al. (1991) described the genus ... amoebae (La Scola & Raoult, 1999). These co-culture studies did indeed demonstrate that A. felis has the ability to grow associated with amoebae, leading us to.
Feb 23, 2018 ... As expected, we observed that all of the samples expressed genes typically expressed in fibroblasts and lacked expression of other lineage-specific genes ...... Izquierdo, E. et al. Synovial fibroblast hyperplasia in rheumatoid arthritis: clinicopathologic correlations and partial reversal by anti-tumor necrosis ...
Hospital Do Rim E Hipertensao, Sa˜o Paulo, Brazil; Merck Research Laboratories, Merck & Co., Inc., Whitehouse Station, New. Jersey; and Department of ... 2 Dr. Brenner's current address is Department of Medicine, Renal Divi- population, suggesting that the risk ... Keane et al: The RENAAL Study. 1500 of the increase in ...
Dec 3, 2017 ... Clinical Question. Among patients with diabetic nephropathy, do ARBs reduce progression to end stage renal disease or death? Bottom Line. Among patients with diabetic nephropathy, losartan reduced doubling of serum creatinine and progression to ESRD but provided no mortality benefit. Major Points.